For the transition period from ____ to ____ Commission File Number 001-33351 _________________________________________________ NEUROMETRIX, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-33351 _________________________________________________ NEUROMETRIX, INC. (Exact name of registrant as specified in it ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K _____________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 04-3308180 (Sta ...

NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Thomas Higgins - Senior VP, CFO & Treasurer Shai Gozani - Founder, Chairman, CEO, President & Secretary Conference Call Participants Jarrod Cohen - Cohen Operator Good morning, and welcome to the NeuroMetrix Fourth Quarter and Full Year 2022 Earnings Call. My name is Latanya, and I will be your moderator on the call. On this call, the company may make statements which are not historical facts an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 4B Gill Street Woburn, Massachusetts 01801 (Address of principal executive offices) ( ...

NeuroMetrix, Inc. (NASDAQ:NURO) Q3 2022 Earnings Conference Call October 20, 2022 8:00 AM ET Company Participants Thomas Higgins - SVP & CFO Shai Gozani - CEO Conference Call Participants Jarrod Cohen - JM Cohen & Company William Church - TGRA Capital Operator Good morning, and welcome to the NeuroMetrix Third Quarter 2022 Earnings Call. My name is Michelle and I will be your moderator on the call. On this call, the company may make statements, which are not historical facts and are considered forward-looki ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-33351 _________________________________________________ NEUROMETRIX, INC. (Exact name of registrant as specified in its ...

NeuroMetrix, Inc. (NASDAQ:NURO) Q2 2022 Earnings Conference Call July 21, 2022 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - President and Chief Executive Officer Operator Good morning and welcome to the NeuroMetrix Second Quarter 2022 Earnings Call. My name is Michelle and I will be your moderator on the call. On this call, the company may make statements, which are not historical facts and are considered forward-looking within the meaning ...

PART I – FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Q1 2022 revenues grew 6.8% to $2.3 million, but a surge in operating expenses resulted in a $958K net loss [Balance Sheets](index=4&type=section&id=Balance%20Sheets) Total assets reached $26.2 million, driven by $23.8 million in cash, with stockholders' equity growing to $24.2 million Balance Sheet Summary (Unaudited) | Account | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $23,769,380 | $22,572,104 | | Total current assets | $25,587,251 | $24,187,859 | | Total assets | $26,248,371 | $24,888,192 | | **Liabilities & Equity** | | | | Total current liabilities | $1,727,254 | $1,365,697 | | Total liabilities | $2,010,463 | $1,672,406 | | Total stockholders' equity | $24,237,908 | $23,215,786 | [Statements of Operations](index=5&type=section&id=Statements%20of%20Operations) Q1 2022 revenues rose 6.8% to $2.3 million, but operating expenses surged 68.1%, leading to a $958K net loss Q1 2022 vs Q1 2021 Statement of Operations (Unaudited) | Metric | Q1 2022 | Q1 2021 | Change (%) | | :--- | :--- | :--- | :--- | | Revenues | $2,302,391 | $2,155,472 | +6.8% | | Gross Profit | $1,793,517 | $1,579,183 | +13.6% | | Gross Margin | 77.9% | 73.3% | +4.6 bps | | Total Operating Expenses | $2,755,507 | $1,639,378 | +68.1% | | Net Loss | ($958,562) | ($59,783) | +1,503.4% | | Net Loss per Share | ($0.14) | ($0.02) | | [Statements of Cash Flows](index=8&type=section&id=Statements%20of%20Cash%20Flows) Q1 2022 net cash used in operations was $740K, offset by $1.94 million from financing, increasing cash to $23.8 million Cash Flow Summary (Unaudited) | Activity | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | ($740,381) | ($33,790) | | Net cash used in investing activities | ($5,395) | ($21,453) | | Net cash provided by (used in) financing activities | $1,943,052 | ($25,803) | | **Net increase (decrease) in cash** | **$1,197,276** | **($81,046)** | | **Cash and cash equivalents, end of period** | **$23,769,380** | **$5,145,167** | [Notes to Unaudited Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Financial%20Statements) Notes detail DPNCheck® and Quell® products, $23.8 million cash sufficient for 12 months, and $1.94 million raised - The company's two primary products are DPNCheck®, a test for diabetic peripheral neuropathy, and Quell®, a wearable device for chronic pain[21](index=21&type=chunk) - Management believes its cash balance of **$23.8 million** as of March 31, 2022, is sufficient to fund operations for at least the **next twelve months**[22](index=22&type=chunk) - One customer accounted for **43%** of total revenues in Q1 2022, up from **36%** in Q1 2021[26](index=26&type=chunk) - In January 2022, the Company issued **292,500 shares** of common stock under its ATM program, receiving net proceeds of **$1,943,052**[40](index=40&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=13&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Q1 2022 revenue grew 6.8% from DPNCheck sales, but operating expenses surged 68.1% due to strategic investments [Our Business and Recent Developments](index=13&type=section&id=Our%20Business%20and%20Recent%20Developments) The company focuses on DPNCheck and Quell, with Quell pursuing FDA Rx indications and Breakthrough Device Designation - The company is investing to expand its DPNCheck business and is developing a next-generation version targeted for a **2022 launch**[46](index=46&type=chunk) - The Quell fibromyalgia indication is under FDA De Novo review, with a decision expected in **H2 2022**. A positive outcome could lead to a commercial launch in **late 2022 or early 2023**[49](index=49&type=chunk) - In January 2022, Quell received FDA **Breakthrough Device Designation** for reducing symptoms of chronic chemotherapy-induced peripheral neuropathy (CIPN)[52](index=52&type=chunk) - The COVID-19 pandemic continues to adversely affect the business, particularly in the diagnostic testing markets for DPNCheck and ADVANCE, slowing new customer acquisition[54](index=54&type=chunk) [Results of Operations](index=15&type=section&id=Results%20of%20Operations) Q1 2022 revenues grew 6.8% to $2.3 million, driven by DPNCheck sales, but operating expenses surged 68.1%, leading to a $958K net loss Q1 2022 vs Q1 2021 Performance | Metric | Q1 2022 | Q1 2021 | Change (%) | | :--- | :--- | :--- | :--- | | Revenues | $2,302,391 | $2,155,472 | +6.8% | | Gross Profit | $1,793,517 | $1,579,183 | +13.6% | | Gross Margin | 77.9% | 73.3% | +4.6 bps | | Operating Expenses | $2,755,507 | $1,639,378 | +68.1% | | Net Loss | ($958,562) | ($59,783) | +1,503.4% | - DPNCheck revenue grew **15.6%** in Q1 2022, attributed to new Medicare Advantage customers and price increases[58](index=58&type=chunk) - The increase in operating expenses reflects investment in DPNCheck initiatives, restructuring commercial capabilities, and costs for potential Quell disease-specific indications[60](index=60&type=chunk) [Liquidity and Capital Resources](index=17&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity is strong with $23.8 million in cash, supplemented by $1.94 million from ATM financing, sufficient for 12 months Key Liquidity Indicators | Indicator | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $23,769,380 | $22,572,104 | | Working capital | $23,859,997 | $22,822,162 | | Current ratio | 14.8 | 17.7 | Q1 2022 Cash Flow Summary | Activity | Amount | | :--- | :--- | | Net cash used in Operating activities | ($740,381) | | Net cash used in Investing activities | ($5,395) | | Net cash provided by Financing activities | $1,943,052 | - The company maintains an effective shelf registration statement, allowing it to raise additional funds through stock sales when considered appropriate[71](index=71&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=19&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company avoids derivative financial instruments, investing cash primarily for principal preservation, with minimal interest rate risk impact - The company's investment strategy for its cash and cash equivalents prioritizes principal preservation and liquidity, with investments mainly in instruments with maturities of **twelve months or less**[74](index=74&type=chunk) [Controls and Procedures](index=19&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls and procedures were effective as of March 31, 2022, with no material changes to internal control over financial reporting - Management concluded that disclosure controls and procedures were effective as of the end of the quarter[75](index=75&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[76](index=76&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=20&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings, with no significant financial impact expected - As of the report date, the company is not involved in any material legal proceedings[77](index=77&type=chunk) [Risk Factors](index=20&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors were reported since the last Annual Report on Form 10-K - No material changes in risk factors were reported since the last Annual Report on Form 10-K[78](index=78&type=chunk) [Other Items (2-6)](index=20&type=section&id=Other%20Items%20(2-6)) The company reported no unregistered equity sales or defaults, with mine safety disclosures not applicable, and exhibits listed - **Items 2, 3, and 5** reported "None"[79](index=79&type=chunk)[80](index=80&type=chunk)[82](index=82&type=chunk) - **Item 4**, Mine Safety Disclosures, is not applicable[81](index=81&type=chunk) - **Item 6** lists the exhibits filed with the 10-Q, including Sarbanes-Oxley certifications and Inline XBRL documents[83](index=83&type=chunk)

NeuroMetrix, Inc. (NASDAQ:NURO) Q1 2022 Earnings Conference Call April 26, 2022 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - President and Chief Executive Officer Operator Good morning and welcome to the NeuroMetrix First Quarter 2022 Earnings Conference Call. My name is Olivia and I will be your moderator on the call. On this call, the company may make statements, which are not historical facts and are considered forward-looking within the ...